[Form 4] Phibro Animal Health Corporation Insider Trading Activity
Jonathan Bendheim, a director of Phibro Animal Health Corp (PAHC), reported acquiring 3,268 restricted stock units (RSUs) on 08/15/2025. These RSUs are contingent rights to receive one share of Class A common stock each and were reported as acquired at a $0 price. Following the reported transaction, Mr. Bendheim beneficially owns 3,268 shares (direct). The RSUs vest in substantially equal installments on each of the first three anniversaries of August 1, 2025, subject to his continued employment through each vesting date. The Form 4 was signed by an attorney-in-fact on 08/19/2025.
Jonathan Bendheim, amministratore di Phibro Animal Health Corp (PAHC), ha comunicato l'acquisto di 3.268 unit脿 azionarie vincolate (RSU) il 15/08/2025. Ciascuna RSU d脿 diritto, al concretizzarsi delle condizioni, a una azione di classe A e sono state riportate come acquisite al prezzo di $0. Dopo l'operazione dichiarata, il sig. Bendheim detiene beneficiariamente 3.268 azioni (dirette). Le RSU maturano in rate sostanzialmente uguali nelle prime tre ricorrenze annuali del 1掳 agosto 2025, subordinatamente al suo proseguimento dell'impiego fino a ciascuna data di maturazione. Il Modulo 4 猫 stato firmato da un procuratore il 19/08/2025.
Jonathan Bendheim, director de Phibro Animal Health Corp (PAHC), declar贸 la adquisici贸n de 3.268 unidades de acciones restringidas (RSU) el 15/08/2025. Estas RSU son derechos condicionados a recibir una acci贸n clase A cada una y se informaron como adquiridas a un precio de $0. Tras la transacci贸n informada, el Sr. Bendheim posee beneficiariamente 3.268 acciones (directas). Las RSU se consolidan en cuotas sustancialmente iguales en cada uno de los tres aniversarios del 1 de agosto de 2025, sujeto a que contin煤e en su puesto hasta cada fecha de consolidaci贸n. El Formulario 4 fue firmado por un apoderado el 19/08/2025.
Phibro Animal Health Corp (PAHC) 鞚挫偓鞚� Jonathan Bendheim鞚� 2025雲� 8鞗� 15鞚检棎 3,268欤检潣 鞝滍暅欤检嫕雼渼(RSU)毳� 旆摑頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 鞚� RSU電� 臧侁皝 氤错喌欤� 韥措灅鞀� A 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ鞚措┌, 旆摑臧�電� $0搿� 鞁犼碃霅橃棃鞀惦媹雼�. 鞁犼碃霅� 瓯半灅 頉� Bendheim 鞌姅 鞁れ鞝侅溂搿� 3,268欤�(歆侅爲 靻岇湢)毳� 氤挫湢頃橁矊 霅╇媹雼�. RSU電� 2025雲� 8鞗� 1鞚检潉 鞁滌瀾鞙茧 觳� 3須� 旮半厫鞚检棎 瓯胳硱 瓯办潣 霃欖澕頃� 牍勳湪搿� 氩犾姢韺呺悩氅�, 臧� 氩犾姢韺呾澕鞐� 鞚措ゴ旮瓣箤歆� 瓿勳啀 瓿犾毄 靸來儨鞐� 鞛堨柎鞎� 頃╇媹雼�. Form 4電� 2025雲� 8鞗� 19鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Jonathan Bendheim, administrateur de Phibro Animal Health Corp (PAHC), a d茅clar茅 l'acquisition de 3 268 unit茅s d'actions restreintes (RSU) le 15/08/2025. Ces RSU constituent des droits conditionnels 脿 recevoir une action de cat茅gorie A chacune et ont 茅t茅 d茅clar茅es acquises au prix de 0 $. 脌 la suite de l'op茅ration d茅clar茅e, M. Bendheim d茅tient b茅n茅ficiairement 3 268 actions (directes). Les RSU se lib猫rent en versements sensiblement 茅gaux 脿 chacun des trois premiers anniversaires du 1er ao没t 2025, sous r茅serve qu'il demeure employ茅 jusqu'脿 chaque date d'acquisition. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 19/08/2025.
Jonathan Bendheim, Direktor von Phibro Animal Health Corp (PAHC), meldete den Erwerb von 3.268 Restricted Stock Units (RSUs) am 15.08.2025. Diese RSUs sind bedingte Rechte, jeweils eine Aktie der Klasse A zu erhalten, und wurden mit einem Erwerbspreis von $0 gemeldet. Nach der gemeldeten Transaktion besitzt Herr Bendheim wirtschaftlich 3.268 Aktien (direkt). Die RSUs werden in im Wesentlichen gleichen Raten an jedem der ersten drei Jahrestage des 1. August 2025 f盲llig, vorbehaltlich seiner fortgesetzten Anstellung bis zu den jeweiligen Vesting-Terminen. Das Formular 4 wurde am 19.08.2025 von einem Bevollm盲chtigten unterzeichnet.
- Director received equity-based compensation (3,268 RSUs), which aligns management incentives with shareholder interests
- Clear vesting schedule disclosed: substantially equal installments on each of the first three anniversaries of 08/01/2025, conditioned on continued service
- Proper Section 16 disclosure filed (Form 4) and signed by attorney-in-fact on 08/19/2025
- None.
Insights
TL;DR: A routine director equity grant of 3,268 RSUs aligns compensation with shareholder value; impact appears minor and standard.
The Form 4 discloses a non-cash acquisition of 3,268 RSUs by a director, recorded at $0, which represent future delivery of Class A shares upon vesting. Vesting occurs in three substantially equal annual installments beginning August 1, 2025, contingent on continued service. This is a compensation-related transaction rather than an open-market purchase or sale and thus is a routine corporate governance disclosure with limited immediate market impact.
TL;DR: Director grant follows common equity compensation practices; disclosure meets Section 16 reporting requirements.
The filing documents a standard restricted stock unit award to a director, with clear vesting terms tied to service through anniversaries of August 1, 2025. The reporting identifies the position (Director), the exact number of RSUs, and the post-transaction beneficial ownership. The Form 4 is properly executed by an attorney-in-fact, satisfying disclosure formalities under the Exchange Act.
Jonathan Bendheim, amministratore di Phibro Animal Health Corp (PAHC), ha comunicato l'acquisto di 3.268 unit脿 azionarie vincolate (RSU) il 15/08/2025. Ciascuna RSU d脿 diritto, al concretizzarsi delle condizioni, a una azione di classe A e sono state riportate come acquisite al prezzo di $0. Dopo l'operazione dichiarata, il sig. Bendheim detiene beneficiariamente 3.268 azioni (dirette). Le RSU maturano in rate sostanzialmente uguali nelle prime tre ricorrenze annuali del 1掳 agosto 2025, subordinatamente al suo proseguimento dell'impiego fino a ciascuna data di maturazione. Il Modulo 4 猫 stato firmato da un procuratore il 19/08/2025.
Jonathan Bendheim, director de Phibro Animal Health Corp (PAHC), declar贸 la adquisici贸n de 3.268 unidades de acciones restringidas (RSU) el 15/08/2025. Estas RSU son derechos condicionados a recibir una acci贸n clase A cada una y se informaron como adquiridas a un precio de $0. Tras la transacci贸n informada, el Sr. Bendheim posee beneficiariamente 3.268 acciones (directas). Las RSU se consolidan en cuotas sustancialmente iguales en cada uno de los tres aniversarios del 1 de agosto de 2025, sujeto a que contin煤e en su puesto hasta cada fecha de consolidaci贸n. El Formulario 4 fue firmado por un apoderado el 19/08/2025.
Phibro Animal Health Corp (PAHC) 鞚挫偓鞚� Jonathan Bendheim鞚� 2025雲� 8鞗� 15鞚检棎 3,268欤检潣 鞝滍暅欤检嫕雼渼(RSU)毳� 旆摑頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 鞚� RSU電� 臧侁皝 氤错喌欤� 韥措灅鞀� A 1欤茧ゼ 氚涭潉 靾� 鞛堧姅 臁瓣贝攵� 甓岆Μ鞚措┌, 旆摑臧�電� $0搿� 鞁犼碃霅橃棃鞀惦媹雼�. 鞁犼碃霅� 瓯半灅 頉� Bendheim 鞌姅 鞁れ鞝侅溂搿� 3,268欤�(歆侅爲 靻岇湢)毳� 氤挫湢頃橁矊 霅╇媹雼�. RSU電� 2025雲� 8鞗� 1鞚检潉 鞁滌瀾鞙茧 觳� 3須� 旮半厫鞚检棎 瓯胳硱 瓯办潣 霃欖澕頃� 牍勳湪搿� 氩犾姢韺呺悩氅�, 臧� 氩犾姢韺呾澕鞐� 鞚措ゴ旮瓣箤歆� 瓿勳啀 瓿犾毄 靸來儨鞐� 鞛堨柎鞎� 頃╇媹雼�. Form 4電� 2025雲� 8鞗� 19鞚检棎 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Jonathan Bendheim, administrateur de Phibro Animal Health Corp (PAHC), a d茅clar茅 l'acquisition de 3 268 unit茅s d'actions restreintes (RSU) le 15/08/2025. Ces RSU constituent des droits conditionnels 脿 recevoir une action de cat茅gorie A chacune et ont 茅t茅 d茅clar茅es acquises au prix de 0 $. 脌 la suite de l'op茅ration d茅clar茅e, M. Bendheim d茅tient b茅n茅ficiairement 3 268 actions (directes). Les RSU se lib猫rent en versements sensiblement 茅gaux 脿 chacun des trois premiers anniversaires du 1er ao没t 2025, sous r茅serve qu'il demeure employ茅 jusqu'脿 chaque date d'acquisition. Le formulaire 4 a 茅t茅 sign茅 par un mandataire le 19/08/2025.
Jonathan Bendheim, Direktor von Phibro Animal Health Corp (PAHC), meldete den Erwerb von 3.268 Restricted Stock Units (RSUs) am 15.08.2025. Diese RSUs sind bedingte Rechte, jeweils eine Aktie der Klasse A zu erhalten, und wurden mit einem Erwerbspreis von $0 gemeldet. Nach der gemeldeten Transaktion besitzt Herr Bendheim wirtschaftlich 3.268 Aktien (direkt). Die RSUs werden in im Wesentlichen gleichen Raten an jedem der ersten drei Jahrestage des 1. August 2025 f盲llig, vorbehaltlich seiner fortgesetzten Anstellung bis zu den jeweiligen Vesting-Terminen. Das Formular 4 wurde am 19.08.2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What did Jonathan Bendheim report on the PAHC Form 4?
What is the vesting schedule for the RSUs reported for PAHC (PAHC)?
At what price were the RSUs reported on the Form 4 for PAHC?
How many shares does Jonathan Bendheim beneficially own after the reported transaction?
Who signed the Form 4 filed for Jonathan Bendheim and when?
